Iveena Delivery Systems, Inc.

Iveena Delivery Systems, Inc. is a for-profit corporate entity registered in SAM.gov since February 2022, with its primary location in Salt Lake City, Utah. The company appears to be focused on medical research and pharmaceutical development, specifically targeting innovative ophthalmological treatments. While limited publicly available information exists about the company's full operational scope, its federal grant history indicates a specialized focus on developing advanced medical interventions for vision-related conditions.

The company has secured multiple federal grant awards from the National Eye Institute, primarily concentrating on developing a novel topical eyedrop treatment called IVMED-85 for controlling and potentially treating myopia. These grants, awarded in September 2023, support research aimed at creating a pharmacological intervention to slow myopia progression by using copper-based formulations to upregulate lysyl oxidase and induce scleral and corneal crosslinking. The research involves extensive preclinical testing, including studies on juvenile guinea pigs, rabbits, and tree shrews to assess safety and efficacy. Additionally, Iveena Delivery Systems, Inc. has engaged in a sub-grant collaboration with the University of Alabama at Birmingham in February 2025, focused on sclera remodeling research, further demonstrating its commitment to advanced ophthalmological research and potential therapeutic innovations for vision-related disorders.